Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBIT (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of EBIT data on record, last reported at -$18.2 million in Q4 2024.

  • For Q4 2024, EBIT fell 92.21% year-over-year to -$18.2 million; the TTM value through Dec 2024 reached -$54.5 million, down 77.14%, while the annual FY2025 figure was -$56.9 million, 4.47% down from the prior year.
  • EBIT reached -$18.2 million in Q4 2024 per SGMT's latest filing, down from -$16.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$6.8 million in Q1 2023 and bottomed at -$18.2 million in Q4 2024.